Cost Savings in Newly Diagnosed Glioblastoma Multiforme (GBM) Trial

Response Criteria: RANO
Site Geo: US
Phase: Il

A clinical stage biotechnology company launched a Phase II prospective clinical trial in patients with glioblastoma. Mid-study, MERIT was engaged to supply the high-quality imaging data and expertise needed to keep the study on track. MERIT’s robust cloud-based software platform, EXCELSIOR, and our operational experience enabled the project team to handle both retrospective and prospective imaging.

The study sites, CRO, and Sponsor all gained advantages from the implementation of EXCELSIOR. Specifically, the Sponsor profited from MERIT’s unique Collect & Hold (C&H) subscription model, which allows early-phase studies to realize the cost-savings of engaging with an experienced imaging vendor. The C&H model provides immediate benefit to a Sponsor’s current study, while also providing future benefits to a company’s drug program.